{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:14:29Z","timestamp":1791976469830,"version":"4.4.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Drug-induced pneumonia is a rare and potentially life-threatening adverse drug reaction. Moxifloxacin is a fluoroquinolone antibiotic with broad-spectrum antimicrobial activity. Despite reports of moxifloxacin-related side effects such as interstitial nephritis, recurrent tendinitis, and pseudoallergic reactions, moxifloxacin-induced pneumonia is exceedingly rare. We report the case of a 45-year-old male who developed fever and cough, and progressed to hypersensitivity syndrome related to drug-induced pneumonia following moxifloxacin therapy. Discontinuation of moxifloxacin led to resolution of fever with significant resolution of pulmonary lesions. Comprehensive laboratory investigations ruled out other causes, confirming drug-induced pneumonia due to moxifloxacin. This case report provides typical clinical manifestations and pulmonary imaging changes, as well as an analysis of differential diagnosis of pulmonary lesions and key management strategies. The case and related literature review contribute to enhancing our understanding of moxifloxacin-related pneumonia, with important clinical significance in promptly correcting adverse reactions and improving patient outcomes.<\/jats:p>","DOI":"10.3389\/fmed.2025.1467001","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T05:14:18Z","timestamp":1746594858000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Drug-induced pneumonia caused by moxifloxacin and a literature review"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqiu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenjing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daohui","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guansong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3390\/jcm9041045","article-title":"Prediction of anti-Cancer drug-induced pneumonia in lung Cancer patients: novel high-resolution computed tomography fibrosis scoring","volume":"9","author":"Gyotoku","year":"2020","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/00130832-200308000-00005","article-title":"Cross-reactivity with drugs at the T cell level","volume":"3","author":"Depta","year":"2003","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/1465-9921-14-133","article-title":"Serum heat shock protein 47 levels in patients with drug-induced lung disease","volume":"14","author":"Kakugawa","year":"2013","journal-title":"Respir Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1634\/theoncologist.2012-0248","article-title":"High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases","volume":"18","author":"Tamura","year":"2013","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1136\/thorax.58.10.872","article-title":"Circulating KL-6 levels in patients with drug induced pneumonitis","volume":"58","author":"Ohnishi","year":"2003","journal-title":"Thorax"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s11547-010-0608-y","article-title":"Prospective evaluation of drug-induced lung toxicity with high-resolution CT and transbronchial biopsy","volume":"116","author":"Piciucchi","year":"2011","journal-title":"Radiol Med"},{"key":"ref8","first-page":"36","article-title":"The role of transbronchial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients","volume":"25","author":"Romagnoli","year":"2008","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1148\/radiol.2243011236","article-title":"Drug-induced pneumonitis: thin-section CT findings in 60 patients","volume":"224","author":"Akira","year":"2002","journal-title":"Radiology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1001\/jama.2019.15468","article-title":"Oral Lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial","volume":"322","author":"Alexander","year":"2019","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1086\/319370","article-title":"Mechanisms of action of antimicrobials: focus on fluoroquinolones","volume":"32","author":"Hooper","year":"2001","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/cid\/ciab641","article-title":"Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children","volume":"74","author":"Radtke","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2174\/0929867013373435","article-title":"Adverse reactions to fluoroquinolones. An overview on mechanistic aspects","volume":"8","author":"De Sarro","year":"2001","journal-title":"Curr Med Chem"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/00365540410019390","article-title":"Recurrent tendinitis after treatment with two different fluoroquinolones","volume":"36","author":"Burkhardt","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1471-2369-11-19","article-title":"Biopsy proven acute interstitial nephritis after treatment with moxifloxacin","volume":"11","author":"Chatzikyrkou","year":"2010","journal-title":"BMC Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e47426","DOI":"10.7759\/cureus.47426","article-title":"Bilateral acute Iris Transillumination syndrome following Oral moxifloxacin overdose","volume":"15","author":"Mendez","year":"2023","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/jat.3758","article-title":"Comprehensive lipid profiling of bleomycin-induced lung injury","volume":"39","author":"Saito","year":"2019","journal-title":"J Appl Toxicol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1398-9995.2010.02460.x","article-title":"In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones","volume":"66","author":"Aranda","year":"2011","journal-title":"Allergy"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12890-022-02064-1","article-title":"A typical presentation of moxifloxacin-induced DRESS syndrome with pulmonary involvement: a case report and review of the literature","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Pulm Med"},{"key":"ref20","first-page":"72","article-title":"Moxifloxacin-associated drug hypersensitivity syndrome with drug-induced hypersensitivity pneumonitis","volume":"18","author":"Son","year":"2008","journal-title":"J Investig Allergol Clin Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2222.2006.02402.x","article-title":"T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity","volume":"36","author":"Schmid","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4103\/jpgm.JPGM_535_18","article-title":"Topical moxifloxacin-induced toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"65","author":"Dhavaleshwar","year":"2019","journal-title":"J Postgrad Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archderm.140.12.1537","article-title":"Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure","volume":"140","author":"Nori","year":"2004","journal-title":"Arch Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e1232","DOI":"10.7759\/cureus.1232","article-title":"Pharmacological threat to lungs: a case series and literature review","volume":"9","author":"Irfan","year":"2017","journal-title":"Cureus."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo","year":"2013","journal-title":"Respir Investig"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1215789","DOI":"10.3389\/fonc.2023.1215789","article-title":"Case report: irinotecan-induced interstitial lung disease in an advanced colorectal cancer patient resurfacing decades after allogeneic bone marrow transplantation for aplastic anemia; a case report and narrative review of literature","volume":"13","author":"Baba","year":"2023","journal-title":"Front Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11882-017-0725-y","article-title":"Update on quinolone allergy","volume":"17","author":"Dona","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/cea.12099","article-title":"Hypersensitivity reactions to fluoroquinolones: analysis of the factors involved","volume":"43","author":"Blanca-Lopez","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"ofac106","DOI":"10.1093\/ofid\/ofac106","article-title":"Immediate hypersensitivity to fluoroquinolones: a cohort assessing cross-reactivity","volume":"9","author":"Azimi","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"ref31","first-page":"41","article-title":"Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions","volume":"58","author":"Sovijarvi","year":"1977","journal-title":"Scand J Respir Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1467001\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T05:14:20Z","timestamp":1746594860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1467001\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":31,"alternative-id":["10.3389\/fmed.2025.1467001"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1467001","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"article-number":"1467001"}}